Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial

Sponsor
Tampere University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02590016
Collaborator
(none)
50
1
2
74
0.7

Study Details

Study Description

Brief Summary

Pregnant women with gestational diabetes who are treated with insulin and their daily insulin dose is 30 IU or more will be randomized into two groups. Active treatment group will receive insulin-glucose-infusion during labour. In the observational group, blood glucose level during labour will be monitored and insulin-glucose-infusion is started only if needed. The hypothesis is that there will not be a difference in rate of hypoglycemia between the two groups and that the proportion of observational group participants that need infusion is low.

Condition or Disease Intervention/Treatment Phase
  • Drug: Insulin, Aspart
Phase 4

Detailed Description

Intrapartum blood glucose level has negative correlation to neonatal blood glucose level in type 1 diabetics. In gestational diabetes the correlation is less clear. In the view of current knowledge, it seems that moderately elevated intrapartum blood glucose may not cause neonatal hypoglycemia. There is no consensus of how to treat intrapartum blood glucose level in gestational diabetics. Some studies have implied that most of mothers with gestational diabetes would have normal blood glucose level during labour and hence would not need any intervention if their daily insulin dosage is less than 0,5-1 IU/kg.

Study participants are recruited into the study at Tampere University Hospital Maternity Ward when their daily insulin dose exceeds 30 IU. Randomization is done at 37th gestational week, if vaginal delivery is planned, and HbA1c is measured. Randomization envelope is opened at the delivery ward when active labour begins and treatment of blood glucose level is carried out accordingly. If insulin dose is 1 IU/kg or more, the participant is treated as in active treatment group despite of result of randomization. All neonates will receive milk substitute after birth in labour ward. Plasma glucose is measured immediately if neonate has symptoms of low blood sugar. If not, plasma glucose is measured approximately two hours after birth and after that every 4 hours until plasma glucose is 3,0 mmol/l or more in three consecutive measurements.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: Insulin-Glucose-Infusion Versus Observational Approach - Is There a Difference in Neonatal Hypoglycemia Rate?
Study Start Date :
Sep 1, 2015
Anticipated Primary Completion Date :
Dec 1, 2020
Anticipated Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Insulin-glucose-infusion

Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.

Drug: Insulin, Aspart
Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
Other Names:
  • Novorapid
  • Active Comparator: Observation

    Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.

    Drug: Insulin, Aspart
    Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
    Other Names:
  • Novorapid
  • Outcome Measures

    Primary Outcome Measures

    1. Neonatal hypoglycemia [within 48 hours after birth]

      Neonatal plasma blood glucose < 3 mmol/l

    Secondary Outcome Measures

    1. Moderate neonatal hypoglycemia [within 48 hours after birth]

      Neonatal plasma blood glucose < 2,6 mmol/l

    2. Severe neonatal hypoglycemia [within 48 hours after birth]

      Neonatal plasma blood glucose <2,2 mmol/l and/or demand of treatment

    3. Duration of neonatal blood glucose monitoring [within a week after birth]

    4. Proportion of participants needing insulin-glucose-infusion in the observational arm [during active labour]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • pregnant women with gestational diabetes mellitus and daily insulin dosage of 30 IU or more
    Exclusion Criteria:
    • planned caesarean section,

    • premature birth (< 37 gestational weeks)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Obstetrics and Gynecology Unit: Tampere University Hospital Tampere Finland 33521

    Sponsors and Collaborators

    • Tampere University Hospital

    Investigators

    • Principal Investigator: Elina Kivekäs, MD, Obstetrics and Gynecology Unit: Tampere University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Elina Kivekäs, MD, Tampere University Hospital
    ClinicalTrials.gov Identifier:
    NCT02590016
    Other Study ID Numbers:
    • R15050M
    First Posted:
    Oct 28, 2015
    Last Update Posted:
    Oct 23, 2019
    Last Verified:
    Oct 1, 2019

    Study Results

    No Results Posted as of Oct 23, 2019